Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD6094 film coated · 1 trial · 1 indication
Absolute bioavailability based on AUC0-inf of oral formulation compared to IV adjusted for dose
Assessment of the total radioactivity by measuring the cumulative amount of AZD6094 (savolitinib) excreted (CumAe)
Assessment of the total radioactivity by measuring the cumulative amount of AZD6094 (savolitinib) excreted and expressed as a percentage of the administered dose (CumFe)
| Arm | Type | Description |
|---|---|---|
| AZD6094 (Savolitinib) D5084C00010 | EXPERIMENTAL | All volunteers will receive either a single dose or two doses of AZD6094 (Savolitinib) D5084C00010 |
| Name | Type | Description |
|---|---|---|
| AZD6094 (Savolitinib) film coated tablets 600 mg | DRUG | AZD6094 (Savolitinib) ilm Coated Tablet 200 mg x 3 |
| [14C]-AZD6094 (Savolitinib) Solution for Infusion, 20 μg/mL (NMT 37.0 kBq/5 mL) | DRUG | 14C AZD6094 (Savolitinib) Solution for Infusion (20 μg/mL (NMT 37.0 kBq/5 mL) |
| [14C] AZD6094 (Savolitinib) Oral Solution, 300 mg (NMT 4.1 MBq) | DRUG | 14CAZD6094 (Savolitinib) Oral Solution (300 mg NMT 4.1MBq) |
Inclusion Criteria: 1. Provision of signed and dated, written informed consent prior to any study specific procedures. 2. Healthy male subjects aged 30 to 65 years at the time of signing informed consent with suitable veins for cannulation or repeated venepuncture. 3. Body mass index (BMI) of 18.0 ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
AZD6094 film coated is an investigational small molecule being developed for the treatment of cancer. It is currently in Phase 1 clinical development. The drug has been studied in a completed clinical trial involving healthy male subjects to assess its bioavailability and metabolism.
AZD6094 film coated is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The company is conducting clinical research on this investigational oncology drug.
AZD6094 film coated is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied for its safety, tolerability, and pharmacokinetic properties in early-stage clinical trials.
AZD6094 film coated has been studied in one clinical trial with the identifier NCT04675021. This was a Phase 1 study titled 'Absolute Bioavailability and ADME Study of Savolitinib in Healthy Male Subjects.' The trial was completed and enrolled 8 healthy male participants in the United Kingdom.
Yes, AZD6094 film coated is also known as savolitinib. The clinical trial NCT04675021, which studied AZD6094 film coated, is titled 'Absolute Bioavailability and ADME Study of Savolitinib in Healthy Male Subjects,' confirming that the drug is referred to by both names.